{"nctId":"NCT05273749","briefTitle":"A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia","startDateStruct":{"date":"2022-04-06","type":"ACTUAL"},"conditions":["Fibromyalgia"],"count":457,"armGroups":[{"label":"TNX-102 SL Tablet, 5.6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL Tablet, 5.6 mg"]},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SL Tablet"]}],"interventions":[{"name":"TNX-102 SL Tablet, 5.6 mg","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient is male or female 18 to 65 years of age, inclusive.\n* The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)\n\nExclusion Criteria:\n\n* The patient has been diagnosed with infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attacks within past 2 years is exclusionary), or meets criteria for other type of systemic autoimmune disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.","description":"Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores. Scores range from 0 to 10 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of \"Very Much Improved\" or \"Much Improved\" at the Week 14 Endpoint","description":"The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint","description":"Change from Baseline in the FIQ-R Symptoms domain score at the Week 14 endpoint. Scores on the symptoms domain range from 0 to 90 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":null},{"groupId":"OG001","value":"-8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint","description":"The FIQ-R is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":null},{"groupId":"OG001","value":"-6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint","description":"The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":null},{"groupId":"OG001","value":"-4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint","description":"The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":null},{"groupId":"OG001","value":"-4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint","description":"Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-1.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":231},"commonTop":["Hypoaesthesia oral","Product taste abnormal","Paraesthesia oral","Tongue discomfort"]}}}